Belgium's Elbion will collaborate with Wyeth on a new schizophrenia drug. Elbion stands to gain up to $110 million in the deal. Elbion's research has focused on inhibiting PDE 10 to improve the function of neurons. Wyeth also struck a deal with Nautilus to develop a new therapy for hemophilia B, though no financial details were provided for that pact. Release on Elbion; Release on Nautilus